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Introduction
Anti-retroviral therapy (HAART) has reduced tradi-
tional HIV-associated disease and death (1). Cardio-
vascular disease (CVD) has emerged as a major cause
of morbidity and mortality in HIV following initial
reports of dyslipidaemia (2–4), probably as a result of
the combination of the pro-inﬂammatory effects of
HIV infection, an increased prevalence of traditional
risk factors (RFs) and the effects of HAART (5–8).
Cardiovascular disease risk screening is an increas-
ing priority in national health care strategies (9).
Risk is calculated using tools derived from epidemio-
logical studies including the USA Framingham study
(10), UK primary care databases (QRISK) (11) and
European prospective cohort studies (SCORE) (12).
In all these calculators, CVD or CHD risk is calcu-
lated using age, gender, smoking, systolic blood pres-
sure (SBP) and total cholesterol: high-density
lipoprotein cholesterol (TC : HDL-C) ratio (13). Ad
hoc adjustments can be made to CVD risk factor
proﬁles to add the effects of family history of prema-
ture CHD, ethnicity and obesity (13). HIV cohorts
in the UK, and most of the developed world, are an
‘ageing population’, and hence there is an increasing
need to focus on CVD. Traditional CVD RFs are
increased in HIV populations (14,15) and seem to
predict risk in a similar fashion to uninfected popu-
lations (16).
This study was designed to describe the CVD RF
burden in a large HIV cohort and to apply these
ﬁndings to recommendations for clinical practice.
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SUMMARY
Aims: The aim of this study is to determine the cardiovascular disease (CVD) risk
proﬁle of a large UK HIV cohort and how highly active antiretroviral therapy
(HAART) affects this. Methods: It is a cross-sectional study within a large inner
city hospital and neighbouring district hospital. A total of 1021 HIV positive outpa-
tients representative of the complete cohort and 990 who had no previous CVD
were included in CVD risk analysis. We recorded demographics, HAART history and
CVD risk factors. CVD and coronary heart disease (CHD) risks were calculated
using the Framingham (1991) algorithm adjusted for family history. Results: The
non-CVD cohort (n = 990) was 74% men, 51% Caucasian and 73.1% were on
HAART. Mean age was 41 ± 9 years, systolic blood pressure 120 ± 14 mmHg,
total cholesterol 4.70 ± 1.05mmol⁄l, high-density lipoprotein-C 1.32 ±
0.48 mmol⁄l and 37% smoked. Median CVD risk was 4 (0–56) % in men and
1.4 (0–37) % in women; CHD risks were 3.5 (0–36) % and 0.6 (0–16) %. CVD
risk was > 20% in 6% of men and 1% of women and > 10% in 12% of men
and 4% of women. CVD risk was higher in Caucasians than other ethnicities; the
risk factor contributing most was raised cholesterol. For patients on their ﬁrst HA-
ART, increased CHD risk (26.2% vs. 6.5%; odds ratio 4.03, p < 0.001) was
strongly related to the duration of therapy. Conclusions: Modiﬁable risk factors,
especially cholesterol, and also duration of HAART, were key determinants of CVD
risk. Discussion: Regular CHD and⁄or CVD risk assessment should be performed
on patients with HIV, especially during HAART therapy. The effect of different
HAART regimens on CHD risk should be considered when selecting therapy.
What’s known
There is a higher incidence of observed
cardiovascular disease in HIV patients, and this is
increased with HIV therapy. Much of the increase
has been ascribed to smoking within patients with
high risk lifestyle, and the contribution of therapy
and its duration to increasing cholesterol is
uncertain.
What’s new
This study demonstrates that cholesterol, rather
than smoking, is the most important contributor to
increased predicted CV ⁄coronary heart disease risk
(CHD) risk in our HIV cohort. It also shows that
duration of HAART is key, and hence has important
implications for the screening and management of
patients with HIV infection.
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Setting
Cardiovascular risk evaluation and antiretroviral
therapy (CREATE) is a cross-sectional study looking
at estimated 10-year CVD and CHD risk, and the
metabolic syndrome in HIV, and this study, CRE-
ATE 1, concentrates on the former aspects. Recruit-
ment was from a large inner London teaching
hospital with a large HIV cohort (exceeding 2500)
and a medium-sized local district hospital with a
more afﬂuent demographic.
Study population
Patients at both hospitals are from a diverse ethnic
and socioeconomic group. The study recruited from
June 2005 to September 2006.The protocol was
approved by the St Thomas’ Hospital Ethics Com-
mittee. To minimise selection bias, all HIV-infected
outpatients were eligible providing they were regular
attendees for their general HIV care and were not
pregnant. Patients were not recruited from specialist
clinics, such as the lipodystrophy or hepatitis
co-infection clinics, to avoid unfair weighting of
patients with metabolic issues. These patients were
still open to study entry from their general HIV
clinic attendance. The research staff identiﬁed clinics
for inclusion, and all such patients were offered entry.
Data collection
A structured proforma was used to collect data on
demographics, basic anthropometry, HIV and
HAART history, current CD4 cell counts, HIV viral
loads and details of co-infections. Ethnicity was self
reported and categorised as: Afro-Caribbean, black
African, white (Caucasian), Asian and other. Details
of HAART were recorded, including the date of
commencement, protease inhibitor use and the cur-
rent regimen.
Anthropometric, physiological and biochemical
parameters required to deﬁne cardiovascular risk
(CVR) and the metabolic syndrome were collected.
The use of anti-atheroma therapies, including
antithrombotic, antihypertensive, lipid-lowering and
hypoglycaemic drugs, was collected, and the use of
recreational drugs recorded. Weight, height, waist
circumference and blood pressure were measured by
trained experienced research nurses or doctors using
standard criteria. Blood pressure was measured in
the sitting position after 5 min rest with an Omron
320 (Henﬁeld, West Sussex, UK) automated system
calibrated to British Hypertension Society standards.
Blood lipids were measured fasting when possible,
and assayed on a Roche Hitachi (Lewes. Sussex, UK)
platform by standard techniques of CHOD-PAP for
cholesterol and a non-ionic precipitation method for
HDL-cholesterol. Data were entered directly onto the
proforma during clinic attendance. Missing informa-
tion on the database was checked with the source
data, clinical notes, on scheduled review. The data-
base was regularly cross-checked with the source
data.
The estimated risk of CVD and CHD was calcu-
lated using the Framingham (1991) (10) equation
recommended for UK use by both the Joint British
Societies Guidelines (2005) (17) and the National
Institute for Health and Clinical Excellence (NICE)
guidelines (2008) (18). No adjustment was made for
ethnicity as the population was of diverse origin and
no speciﬁc correction factors exist for West Africans.
CHD risk relates to the development of coronary
heart disease (MI, CHD death, angina, coronary
insufﬁciency). CVD additionally includes stroke, con-
gestive heart failure and peripheral vascular disease.
To assess CVD risk in a control population, data
were compared with the QRESEARCH database (19),
which is derived from a UK general practice popula-
tion, a self-referred CVD risk programme in the UK
(HEART-UK⁄Unilever CVD risk assessment study)
(20) and with the combined DAD cohort studies of
CVR in HIV (15,21) (Table 1A–C). The DAD study
(data collection on adverse events of anti-HIV drugs)
is a collaboration of eleven prospective cohorts of
HIV-infected individuals from across Europe, Austra-
lia and the US, totalling over 30,000 participants.
Statistical analysis
Statistical analysis was performed with spss (Chelten-
ham, Gloucestershire, UK). This analysis included
only patients free of pre-existing CHD diagnoses.
Estimated 10-year CHD⁄CVD risk was summarised
using medians and the proportion with values
> 10% and > 20% per decade. Subgroups were com-
pared using Chi-squared or Fishers exact test for cat-
egorical variables and Mann–Whitney tests for
continuous variables. Logistic regression was used to
assess the association of HAART use with 10-year
CHD risk > 10% and to investigate the extent to
which this association was independent of traditional
CHD risk factors. The association of duration of
HAART use with 10-year CHD risk was examined in
a subgroup of patients on ﬁrst line HAART.
Results
Patient characteristics
A total of 1021 patients were recruited, of which 990
were free of pre-existing CVD (Table 1). For the
purposes of data presentation and analysis
(Table 1A,B), the total numbers in CREATE1 were
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purposes of comparison with the DAD study
cohorts, which included CVD, data from the com-
plete cohort of 1021 were used (Table 1C).
The majority, 74%, were men, 50.8% were white,
6.9% Afro-Caribbean, 33.3% African (various), 1.9%
Asian and 6.9% from other ethnic groups. Men who
have sex with men (MSM) comprised 43.9%, and
41% were heterosexual. Intravenous drug abuse was
reported by 1.65%. The median HIV viral load was
50 copies⁄ml and CD4 count 406 cells⁄mm
3, and
73.1% were on HAART. CVD was present in 3% of
both men and women, and diabetes in 3% and 2%,
respectively. The mean (±SD) age was 41 ± 9 years
(48.6% ‡ 40 years). Current or recent smoking
(within 5 years) was reported by 37% and was com-
moner in whites (51% vs. 23%; p = 0.02) than black
Africans. The SBP was 120 ± 14 mmHg, and 11%
had a SBP > 140 mmHg. The TC was 4.70 ±
1.05 mmol⁄l and HDL-C was 1.32 ± 0.48 mmol⁄l.
An elevated TC (> 5 mmol⁄l) was present in 35.6%.
HDL-C < 1 mmol⁄l in men or < 1.2 mmol⁄li n
women was found in 33%. An elevated TC : HDL
ratio > 5 was present in 18.7% and > 6 in 7.6%.
Lipid-lowering drugs had been prescribed in 10.8%.
The male population in CREATE 1 was younger
(41 years vs. 52 years), contained more smokers
(45% vs.13%), had lower SBP (121 mmHg vs.
140 mmHg), slightly lower TC (4.7 mmol⁄l vs.
5.1 mmol⁄l) and less established CHD than those
self-referring for CVD risk screening in the HEART-
UK⁄Unilever study. Similarly, women recruited to
CREATE 1 were younger (39 years vs. 52 years), had
lower SBP (118 mmHg vs. 134 mmHg) and choles-
terol (4.7 mmol⁄l vs. 5.2 mmol⁄l) and less CHD
(3% vs. 9%), but more smoked (16% vs.13%).
HEART-UK⁄Unilever participants were markedly dif-
ferent in ethnic origin (92% were non-Caucasian)
and were more centrally obese (64% vs. 40%). The
population was similar to that recruited to the DAD
study cohorts (Table 1C) except for marginally lower
TC (4.7 mmol⁄l vs. 5.0 mmol⁄l), higher HDL-C
(1.23 mmol⁄l vs. 1.1 mmol⁄l) and body mass index
(BMI) (24.7 kg⁄m
2 vs. 23 kg⁄m
2) and a lower preva-
lence of current smoking (37% vs. 51%).
Cardiovascular and CHD
The median CVD risk was 4 (0–56) %⁄decade in
men and 1.4 (0–37) %⁄decade in women, whereas
CHD risks were 3.5 (0–36) %⁄decade and 0.6 (0–16)
%⁄decade, respectively. CVD risk was > 20% in 6%
of men and 1% of women and > 10% in 12% of
men and 4% of women, whereas CHD risk exceeded
10% in 13% of men and 2% of women and was
> 20% in 2% of men but no women. CVD risk was
Table 1 (A–C) Clinical characteristics of male and female patients attending a
HIV service in the UK compared with a general cardiovascular risk screening
group in the UK and the DAD cohort study
Cohort without
CVD (male; n = 737)
HEART-UK
(male; n = 27,776)
(A) HIV positive men in CREATE 1 compared with a HEART-UK population
Age 41.2 ± 9.2 51.5 ± 16.2*
Caucasian (%) 65 Not available
Smoking (%) 45* 13.4
Systolic blood pressure (mmHg) 121 ± 14 140 ± 17*
Hypertension (%) 12 13
Total cholesterol (mmol⁄l) 4.70 ± 1.05 5.10 ± 1.00*
HDL-cholesterol (mmol⁄l) 1.25 ± 0.44 1.20 ± 0.40
Diabetes (%) 2 4
CHD (+) (%) NA 11
BMI (kg⁄m
2) 24.6 ± 3.8 -
Waist > 102 cm (%) 24 25
Cohort without CVD
(female; n = 253)
HEART-UK
(female; n = 43,261)
(B) HIV-positive women in CREATE 1 compared with a HEART-UK population
Age 38.8 ± 8.8 52.1 ± 15.4*
Caucasian (%) 9 Not available
Smoking (%) 16* 12.7
Systolic blood pressure (mmHg) 118 ± 14 134 ± 19*
Hypertension (%) 9 13
Total cholesterol (mmol⁄l) 4.74 ± 1.04 5.20 ± 1.00*
HDL-cholesterol (mmol⁄l) 1.54 ± 0.54 1.50 ± 0.40
Diabetes (%) 2 3
IHD (+) (%) NA 8.7*
BMI (kg⁄m
2) 27.8 ± 6.1 -
Waist > 88 cm (%) 64* 40.1
Complete CREATE 1 cohort,
including CVD (n = 1022) DAD (n = 23,468)
(C) Complete cohort in CREATE 1 compared with subjects in the DAD study
Age 40 (35–46) 39 (34–47)
Caucasian (%) 51 –
Male (%) 76 75
MSM 44 45
Smoking (%) 37* 51
Systolic blood pressure (mmHg) 120 (110–130) 120 (110–130)
Hypertension (%) 12* 8.5
Total cholesterol (mmol⁄l) 4.7 (3.9–5.3) 5.0 (4.2–6.0)
HDL-cholesterol (mmol⁄l) 1.23 (1.00–1.53) 1.1 (0.9–1.4)
Diabetes (%) 3 2.5
IHD (+) (%) 3 1.4
CD4 count (mm
3⁄l) 406 (289–562) 418 (255–612)
Viral Load (log) < 1.70 (< 1.70–3.54) < 2.7 (< 2.7–6.9)
BMI (kg⁄m
2) 24.7 (22.3–27.7) 23 (21–25)
Waist > 102 cm (%) 24 –
Family history early CHD (%) 13 11.7
IHD, ischaemic heart disease, CREATE 1, cardiovascular risk evaluation and antiretroviral
therapy; HDL, high-density lipoprotein; CHD, coronary heart disease; BMI, body mass index;
MSM, men who have sex with men.
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UK⁄Unilever study, although our patients were sig-
niﬁcantly younger and had a higher prevalence of
smoking (Table 1A,B). There was suggestion of
increased CHD risk among men in our cohort com-
pared with general population seen by general practi-
tioners (19). In this study for men aged 45–55 years,
CHD risk > 15% was present in 14.7% compared
with 7.76% in the control group. There were insufﬁ-
cient data to make meaningful comparisons for
women.
Analyses were performed to investigate the associa-
tions of gender, ethnicity (Caucasians vs. non-Cauca-
sians), risk group (MSM vs. heterosexuals) and use
of HAART with CVD and CHD risk. The median
CVD and CHD risks were 4.4% and 2% for men
and 1.4% and 1% for women (p < 0.001). The pro-
portions with CVD risk > 10% were 21.8% vs. 3.8%
(p < 0.001) and for CHD risk ‡ 10% 16.4% vs. 0.4%
(p < 0.001), respectively. Statistically signiﬁcant dif-
ferences in CHD risk were also seen for those in
older age groups, and groups stratiﬁed by TC above
or below 5 mmol⁄l, SBP above or below 140 mmHg
and smokers vs. non-smokers (data not shown).
Compared with non-Caucasians, Caucasians had
greater CVD and CHD risks, and approximately a
3-fold increase in the prevalence of CHD risk
> 10% or CVD risk > 20%. These differences could
partly be attributed to more men among our Cauca-
sians (96% vs. 53%; p < 0.001) hence more MSM
individuals (73% vs. 13%; p < 0.001), higher viral
load (2.63 vs. 2.33; p < 0.001), but also higher med-
ian CD4 count (432 vs. 381; p < 0.001), more
smoking (50% vs. 22%; p < 0.001) and lower HDL-
C (1.22 vs. 1.42 mmol⁄l; p < 0.001). No signiﬁcant
differences in CVD or CHD risk were observed in
MSM compared with male heterosexuals, despite
signiﬁcant differences in age (40 vs. 42 years;
p < 0.001), smoking (50% vs. 37%; p < 0.001) and
prevalence of drug-treated hypertension (5% vs.
11%; p = 0.003) and higher viral loads (2.66 vs.
2.33; p < 0.001) and CD4 counts (434 vs. 381;
p < 0.001).
HAART use
A total of 705 patients out of 973 were on HAART;
245 were on their ﬁrst line regimen, of whom 44.1%
had used HAART for < 1 year, and about a third
and a quarter used HAART for 1–3 years and
> 3 years, respectively.
Patients on HAART had signiﬁcantly raised med-
ian CVD risk (3.57% vs. 2.34%; p = 0.01) and CHD
(0.64% vs. 0.38%; p < 0.001) risk, associated with
increased age (42 vs. 37 years, p < 0.001), higher TC
(4.86 vs. 4.24 mmol⁄l; p < 0.001), but also lower
viral load (1.96 vs. 4.02; p < 0.001) and higher HDL-
C (1.39 vs. 1.12 mmol⁄l; p < 0.001) (Table 2).
The duration of HAART was associated with
CVD and CHD risk. For this analysis, only the 245
participants on ﬁrst line therapy were included to
avoid confounding from previous HAART use. The
proportions with 10 year CVD and CHD risk > 20%
for those on HAART < 1 year were 4.3% and 0.8%
and for ‡ 3 years exposure 11% and 4.8%, respec-
tively (p = 0.01). These differences were statistically
signiﬁcant for both Caucasians and non-Caucasians.
A further analysis was performed to deﬁne variables
within this group associated with increased CVD
risk with duration of HAART. Age ‡ 40 years, TC
‡ 5 mmol⁄l and SBP‡ 140 mmHg were all more
common in the group who had been on HAART
the longest. Conversely, there were fewer persons
with low HDL-C in the ‡ 3 year compared with
< 1 year HAART groups, and the TC⁄HDL ratio did
not vary with length of time on HAART (Table 3B).
Smoking was not a factor that contributed to a
higher CHD risk for those on HAART for longer
periods (as a group), as there were similar propor-
tions of smokers in each group regardless of the
duration on HAART.
The contribution that each Framingham equation
variable made to estimated CVD⁄CHD risk in
patients on HAART was investigated. The unadjusted
odds ratio for high CVD risk was 1.36 (0.92, 2.00)
for HAART users vs. non-users. Adjusting for age
and gender, the odds ratio fell to 1.13 (0.72, 1.80).
Similarly, the unadjusted odds ratio for high CHD
risk was 1.59 (0.99, 2.57) for HAART users vs. non-
users and after adjustment for age and gender, the
odds ratio fell to 1.02 (0.57, 1.85). This excess risk
was accounted for after adjustment for SBP, smoking
Table 2 Association of factors with current HAART use
n⁄N (%)
Using HAART
(n = 705)
Not using HAART
(n = 258)
p value (Chi-squared⁄
Fishers exact test)
Male 509⁄705 (72.2) 204⁄258 (79.1) 0.031
Age > 40 years 388⁄705 (55.0) 83⁄258 (32.2) < 0.001
Caucasian 330⁄690 (47.8) 149⁄253 (58.9) 0.003
MSM 279⁄705 (39.6) 144⁄258 (55.8) < 0.001
Chol > 5 mmol⁄l 296⁄705 (42.0) 47⁄258 (18.2) < 0.001
Lipid-lowering drug use 88⁄705 (12.5) 6⁄258 (2.3) < 0.001
HDL < 1 mmol⁄l 134⁄705 (19.0) 95⁄258 (36.8) < 0.001
TC⁄HDL ratio > 4.5 192⁄705 (27.2) 88⁄258 (34.1) 0.037
Sys BP > 140 mmHg 77⁄705 (10.9) 29⁄258 (11.2) 0.89
Smoker 250⁄705 (35.5) 107⁄258 (41.5) 0.087
HAART, highly active antiretroviral therapy; MSM, men who have sex with men; HDL, high-
density lipoprotein; TC, total cholesterol; Sys BP, systolic blood pressure.
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after correction for cholesterol alone (0.63 (0.34–
1.20).
A similar analysis was performed for 245 patients
on ﬁrst-time HAART according to the duration of
HAART (< 1 year, 1–3 years, ‡ 3 years) (Figure 1).
The unadjusted odds ratio for high CHD risk was
1.24 for 1–3 years and 5.13 for ‡ 3 years groups,
compared with the < 1 year group (Figure 1). Again
the greatest contribution to the excess risk in both
the 1–3 years and ‡ 3 years groups was TC, as indi-
cated by the comparatively large fall in odds ratio
after adjustment for TC.
Discussion
The increased frequency of observed CHD in HIV-
infected vs. uninfected patients has focused attention
on appropriate strategies to prevent cardiovascular
disease in this population. Observational cohort
studies have shown an increase in observed CVD
events with the use of HAART, particularly with pro-
tease inhibitors (15,21). Some of the protease inhibi-
tor effect can be attributed to drug-associated
dyslipidaemia (21).
Among our UK-based cohort in CREATE1, levels
of CVD and CHD risk appeared high compared with
similar age groups in the general population, with a
higher prevalence of smoking and hypercholesterola-
emia. The average CVD and CHD risks in our
cohort were 6.0% and 4.15%, respectively. The CHD
risk was much lower than the 7–7.4% CHD risk seen
in the Italian SIMONE cohort of HIV-infected
patients (22,23), where the prevalence of elevated
CVD risk > 10% was 17% and CHD risk> 10% was
10%. CVD risk > 20% was present in 4.9% and
CHD risk > 20% in 1.6%. Other cohort studies of
HIV-infected patients have shown higher prevalence
of CHD risk > 10% of 23% and > 20% in 8% (24)
or 11% (14). In the DAD study, the same version of
the Framingham risk scoring tool used in our study
determined that the CHD risk was 2.4% (25). Thus,
the population recruited to CREATE 1 is at the
intermediate risk for CVD compared with other HIV
cohort studies. The CHD risk in the CREATE 1
cohort was elevated compared with a similar cohort
of the general population from the QRESEARCH
database, and the proportions with elevated CVD
risk were similar to sex-matched age cohorts from
the self-selected general population recruited for the
HEART-UK⁄Unilever Study (20).
We found in CREATE 1 that caucasians were
much more likely to have a CVD or CHD risk
‡ 10% than non-Caucasians. Even amongst the non-
Caucasians, the proportion with raised CVD or CHD
risk increased with the duration of HAART (from
3.5% with < 1 year use to 17.9% with > 3 years use;
n = 245 ﬁrst line users only). While many guidelines
recommend adjustment of the Framingham risk for
additional risk factors, this remains controversial.
The Framingham risk calculator was derived from
data on a mainly white working class population and
predicted the correct proportion at risk in patients
with HIV in DAD cohort study (25). Aside from
Caucasians, the largest ethnic sub-group in CREATE
1 was African and diverse with respect to country of
origin. Secondary adjustment for ethnicity is possible
and tends to reduce CVD and CHD risk in African-
derived populations compared with Asian or Cauca-
sian populations in the UK (26), but is limited and
is mostly based on West Africans. The degree of
adjustment required for other African populations
has not been determined, but CVD risk is elevated in
Table 3 (A, B) Mean lipid values according to HAART
use
HAART
now
Total
cholesterol
HDL-
cholesterol
TC : HDL
ratio
(A) Mean total cholesterol, HDL-cholesterol and
total⁄HDL ratio by current HAART use
No Mean 4.28 1.14 4.05
N 258 258 258
SD 0.89 0.34 1.32
Yes Mean 4.88 1.40 3.84
N 705 705 705
SD 1.06 0.51 1.34
Total Mean 4.72 1.33 3.90
N 963 963 963
SD 1.05 0.49 1.34
Years
1st line
Total
cholesterol
HDL-
cholesterol
TC : HDL
ratio
(B) Mean total cholesterol, HDL-cholesterol and
total⁄HDL ratio by years on ﬁrst line
< 1 Mean 4.50 1.23 3.98
N 108 108 108
SD 0.97 0.42 1.27
1–3 Mean 4.81 1.41 3.75
N 76 76 76
SD 0.96 0.50 1.33
‡ 3 Mean 5.31 1.49 3.91
N 61 61 61
SD 0.86 0.49 1.39
Total Mean 4.80 1.35 3.89
N 245 245 245
SD 0.99 0.48 1.32
HDL, high-density lipoprotein; HAART, highly active antiretrovi-
ral therapy; TC, total cholesterol.
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as CVD and CHD risks had already been adjusted
for family history, further adjustment was not per-
formed (17). In Afro-Caribbean general population,
the age-adjusted prevalence of CVD is 0.61, but there
are no data on patients with HIV with this ethnic
background in the UK.
In our study, the increased predicted CVD and
CHD risk among Caucasians is at variance with a
large prospective HIV cohort study of observed acute
myocardial infarctions from the USA (29), where
African-American race was a signiﬁcant predictor of
acute myocardial infarction, with a relative risk 1.43
compared with non-African-Americans. This may
well reﬂect the differences in underlying risk factors
between the 2 cohorts, such as proportions of smok-
ers, differences in BMI and dysglycaemia and effects
of social deprivation. Similar discrepancies were
found between our cohort and the same US cohort
in respect of gender, as among our female patients
there were very few with even a moderately high pre-
dicted CVD or CHD risk. There was a marked
increase in the relative rate of women with observed
acute myocardial infarctions in the same US HIV
cohort, with a relative risk of 2.98, compared with
the control population (29).
In this study, smoking was less frequent than in
the DAD cohort (37% vs. 52%) and showed pro-
nounced ethnic and gender differences. Smoking was
most associated with CVD risk in men and was com-
moner in Caucasians. In women, the prevalence of
smoking was slightly increased compared with the
general population. A large proportion of the cohort
was heterosexual black African, where smoking was
less prevalent than among Caucasians (23% vs.
51%). Therefore, the relative contribution of smok-
ing to CVD risk in this population is likely to be
lower than in other studies.
The greatest population-attributable risk in the
INTERHEART study was dyslipidaemia. Dyslipida-
emia is frequent in HIV (25). Dyslipidaemia related
to the duration of HAART therapy contributed most
to an increased predicted CVD and CHD risk
amongst our cohort. The duration of ﬁrst line
HAART use was associated with a CHD risk ‡ 10%,
with a relative risk > 5 for those on HAART for over
3 years compared with those who on HAART for
under 1 year. This ﬁnding replicates those of the
DAD study recruited from 1999 to 2003 (21) and
shows that despite the availability of newer protease
inhibitors that do not signiﬁcantly affect lipid
concentrations, most patients were still receiving
HAART regimens that induced dyslipidaemia and
increased CHD risk.
These ﬁndings provide a rationale for speciﬁc poli-
cies for the management of CVR in people with
HIV, using adaptations of standard guidelines from
the Joint British Societies (17) or NICE (18). This
study demonstrates that management of CVD risk in
HIV patients should consider length of exposure to
HAART as well as ethnicity and gender. Risk calcula-
tors give only broad estimates of risk (30) and addi-
tional risk stratiﬁcation may be required in
intermediate (10–20%) risk patients (31,32). Patients
at 10–20% risk should be prioritised for intensive
lifestyle interventions. Modiﬁable risk factors should
be actively managed, including the use of antihyper-
tensives and lipid-lowering agents where lifestyle
changes such as diet and exercise do not sufﬁce. It is
important for the individual and the patient cohort
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Figure 1 Comparison of coronary heart disease (CHD) risk with length of treatment with highly active antiretroviral
therapy (HAART) before and after adjustment for CHD risk factors. Contribution of CV risk factors to odds ratio (OR)
for 10 year CHD risk > 10% by length of time on HAART. n = 243 ﬁrst line HAART users only (OR Y-axis). First
adjustment for age⁄gender; then sequentially for sBP, smoking and total Chol. The degree of OR drop reﬂects the
contribution of that factor to risk in the ﬁrst place. Biggest OR drop seen when TC corrected for
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body weight (5,6). If these intervention strategies are
not successful in reducing CHD risk, then changing
HAART regimens should be considered (33–35). The
observation that duration of ﬁrst line HAART corre-
lated strongly with CHD risk has clinical implica-
tions for management. It is important that CHD is
assessed before and after treatment, to ascertain the
extent to which the HAART might be contributing
to increased CHD risk. There are a number of anti-
retroviral agents that do not affect lipids to the
extent of other current therapies. These include the
newer generation protease inhibitors, such as ataz-
anavir (36), although this advantage is mitigated in
part by the concomitant use of ritonavir as a phar-
macological enhancer (37). Other agents that have a
favourable lipid proﬁle include raltegravir, an integr-
ase inhibitor (38), as well as some of the agents that
have been available for many years, such as nevira-
pine (34,35).
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